|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Abbott |
| Information provided by: | Abbott |
| ClinicalTrials.gov Identifier: | NCT00063102 |
Purpose
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
| Condition | Intervention | Phase |
|
Breast Cancer |
Drug: ABT-751 |
Phase II |
| Genetics Home Reference related topics: | breast cancer |
| MedlinePlus related topics: | Breast Cancer Cancer |
| Drug Information available for: | Docetaxel Paclitaxel ABT 751 E 7010 |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens |
| Estimated Enrollment: | 40 |
| Study Start Date: | November 2002 |
| Study Completion Date: | August 2004 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contacts and Locations| United States, Florida | |||||
| Clinical Research Network, Inc. | |||||
| Plantation, Florida, United States, 33324 | |||||
| Oncology-Hematology Group of South Florida | |||||
| Miami, Florida, United States, 33176 | |||||
| United States, Georgia | |||||
| Georgia Cancer Specialists | |||||
| Atlanta, Georgia, United States | |||||
| United States, Illinois | |||||
| Northwestern University Medical School Division of Hematology/Oncology | |||||
| Chicago, Illinois, United States, 60611 | |||||
| United States, Indiana | |||||
| Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion | |||||
| Indianapolis, Indiana, United States, 46202 | |||||
| Northern Indiana Cancer Research Consortium | |||||
| South Bend, Indiana, United States | |||||
| United States, Missouri | |||||
| Oncology & Hemotology Associates of Kansas City, PA | |||||
| Kansas City, Missouri, United States, 64111 | |||||
| United States, Texas | |||||
| Texas Oncology | |||||
| Dallas, Texas, United States | |||||
| Abbott |
| Study Director: | Helen Eliopoulos, MD | Abbott |
More Information
| Study ID Numbers: | M02-447 |
| First Received: | June 19, 2003 |
| Last Updated: | November 28, 2007 |
| ClinicalTrials.gov Identifier: | NCT00063102 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|